Category Archives: Events

Challenges in the March Toward an AIDS-Free Generation

By Ben Comer | Published: August 1, 2012

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.

Also posted in Biotech, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Tagged AIDS, Antiretroviral drug, Bill & Melinda Gates Foundation, conference, Gilead Sciences, HIV, HIV/AIDS, NIAID | Leave a comment

Missed Opportunities in Rare Disease

By Ben Comer | Published: July 20, 2012

At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.

Also posted in Corporate Responsibility, Market Access, Regulatory, leadership, patient compliance, patient education | Tagged CBI, orphan diseases, Orphan Drugs, rare diseases, REMS | Leave a comment

BIO 2012: The Case for Collaboration

By Ben Comer | Published: June 19, 2012

Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”

Also posted in Biotech, Europe, FDA, Global, IP, People, R&D, Regulatory, Strategy, Technology, healthcare, leadership | Tagged BIO, CEO, Chris Viehbacher, collaboration, conference, innovation, life sciences, Sanofi | Leave a comment

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.

Also posted in Europe, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Tagged CEO, CEOs, drug safety, Eli Lilly, Financial Times, Global, healthcare reform, innovation, IP, IPAB, Lilly, PhRMA, policy, R&D | 1 Comment

Drug Innovation: Alive and Well at ASCO!

By Guest Blogger | Published: June 6, 2012

By John Otrompke. This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease. Improved results in progression-free survival in clinical trials suggest that many forms of cancer may soon take on a more [...]

Also posted in Guest Blog, R&D | Tagged American Society of Clinical Oncology, ASCO, drug development | 1 Comment